PUBLISHER: The Business Research Company | PRODUCT CODE: 1425244
PUBLISHER: The Business Research Company | PRODUCT CODE: 1425244
Atopic Dermatitis Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on atopic dermatitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for atopic dermatitis? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The atopic dermatitis market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Atopic dermatitis is a chronic dermatological condition characterized by skin dryness and itching. This condition progresses over time and is not contagious through contact.
The main drug classes used to treat atopic dermatitis include corticosteroids, emollients/moisturizers, IL-4 and PDE4 inhibitors, calcineurin inhibitors, antibiotics, and others. Corticosteroids are anti-inflammatory drugs that mimic cortisol and are employed in the treatment of various diseases, including rheumatological conditions, rheumatoid arthritis, lupus, and atopic dermatitis. These drugs can be administered through various modes, such as topical, injectable, and oral, and are available through different distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies.
The atopic dermatitis market research report is one of a series of new reports from The Business Research Company that provides atopic dermatitis market statistics, including atopic dermatitis industry global market size, regional shares, competitors with an atopic dermatitis market share, detailed atopic dermatitis market segments, market trends and opportunities, and any further data you may need to thrive in the atopic dermatitis industry. This atopic dermatitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The atopic dermatitis market size has grown rapidly in recent years. It will grow from $7.51 billion in 2023 to $8.7 billion in 2024 at a compound annual growth rate (CAGR) of 15.9%. The observed growth in the historic period can be attributed to factors such as increased medical understanding and awareness of atopic dermatitis, changes in incidence and prevalence rates, the presence of patient advocacy and support, the evolution of treatment options, and ongoing research and development in the field.
The atopic dermatitis market size is expected to see rapid growth in the next few years. It will grow to $15.27 billion in 2028 at a compound annual growth rate (CAGR) of 15.1%. The anticipated growth in the forecast period can be attributed to advancements in biologic therapies, the development of immunomodulators and small molecule drugs, the emergence of pediatric-specific treatments, innovations in gene therapy and precision medicine, and the integration of digital health solutions. Major trends expected in the forecast period include technological advancements in topical treatments, a focus on pediatric care, increased emphasis on environmental and allergen management, and the use of precision diagnosis tools.
The atopic dermatitis market is poised for significant growth due to the high prevalence of this condition, commonly known as eczema. Atopic dermatitis is characterized by skin dryness and itching, necessitating increased attention for diagnosis and treatment. For instance, the National Eczema Association reported that in 2021, approximately 31.6 million people in the US, constituting around 10% of the population, were affected by eczema, with 9.6 million being children under 18. This emphasizes the urgency for effective measures in managing atopic dermatitis, especially since 80% of those affected experience symptoms before the age of 6. Consequently, the rising prevalence of atopic dermatitis continues to drive growth within the atopic dermatitis market.
The growing demand for personalized medicine is anticipated to contribute significantly to the expansion of the atopic dermatitis market. Personalized medicine involves tailoring medical interventions, including drug therapies, to suit individual patient characteristics, such as genetics and molecular factors. This approach ensures more targeted and effective treatments while minimizing adverse effects. For example, as of October 2022, reports indicated a vast array of over 75,000 genetic testing products and 300 personalized medicines, underlining the surging demand for tailored therapeutic options. This trend is fueling the growth of the atopic dermatitis market by emphasizing more precise and patient-centric treatment approaches.
Innovations in product development are emerging as a pivotal trend within the atopic dermatitis market, with major companies introducing novel solutions to reinforce their market position. Notably, in June 2022, Regeneron Pharmaceuticals Inc., a prominent US-based biotechnology company, secured FDA approval for Dupixent (dupilumab). Dupixent is a medication designed for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis. This groundbreaking drug works by inhibiting the signaling of two critical Type 2 inflammatory sources (IL-4 and IL-13), contributing to the development of various conditions such as eosinophilic esophagitis, prurigo nodularis, chronic rhinosinusitis with nasal polyposis, and asthma. The approval of Dupixent represents a significant advancement in pediatric atopic dermatitis treatment, promising more effective therapeutic options for young patients.
Major companies within the atopic dermatitis market are strategically pursuing product approvals to stimulate revenue growth within their industry. Product approvals signify the official endorsement granted by health regulatory bodies, affirming the safety and effectiveness of pharmaceuticals or treatments for managing inflammatory skin conditions like atopic dermatitis. Notably, in January 2022, AbbVie Inc., a prominent US-based pharmaceutical company, secured FDA approval for Rinvoq. Rinvoq, containing upadacitinib as its active component, belongs to the class of janus kinase (JAK) inhibitors, a targeted synthetic disease-modifying antirheumatic drug. This medication received approval for treating moderate-to-severe atopic dermatitis in both adults and children aged 12 years and above. Rinvoq serves as an alternative when other treatments, including biologic medicines or conventional medications, have been ineffective in managing the condition, or when their usage is not recommended. It is noteworthy that Rinvoq (upadacitinib) can be administered in conjunction with methotrexate or as monotherapy, thereby broadening treatment options for atopic dermatitis patients.
In September 2022, Arcutis Biotherapeutics, a prominent commercial-stage biopharmaceuticals firm headquartered in the United States, finalized the acquisition of Ducentis BioTherapeutics for an undisclosed sum. This strategic acquisition is envisioned to reinforce Arcutis Biotherapeutics' position within the medical dermatology sector while enhancing its capacity to address the unmet medical needs of patients dealing with dermatological conditions. Notably, Ducentis BioTherapeutics, a preclinical-stage biotechnology company also based in the US, specializes in the development of primary treatments targeting atopic dermatitis, aligning with Arcutis Biotherapeutics' commitment to advancing therapies for this skin disorder.
Major companies operating in the atopic dermatitis market report are Sanofi SA, Meda AB, Regeneron Pharmaceuticals Inc., Novartis International AG, Pfizer Inc., AbbVie Inc., Astellas Pharma Inc., Arcutis Biotherapeutics Inc., Asana Biosciences LLC, Dermavant Sciences Inc., Eli Lilly and Company, Galderma SA, Incyte Corporation, Bayer AG, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC, F Hoffmann-La Roche AG, LEO Pharma A/S, Teva Pharmaceutical Industries Ltd., Mylan MV, Allergan PLC, Encore Dermatology Inc., Menlo Therapeutics Inc., Johnson & Johnson, Merck & Co Inc., Roche Holding AG, Valeant Pharmaceuticals International Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Eisai Co. Ltd., Gilead Sciences Inc., Ipsen Biopharmaceuticals Inc., Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals Limited
North America was the largest region in the atopic dermatitis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atopic dermatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the atopic dermatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The atopic dermatitis market consists of sales of biologics, CNI immunosuppressant drugs, and skin barrier emollients. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.